Beyond sequential treatment, it is unknown whether the ICI/VEGF combination is more efficacious than TACE for the upfront treatment of intermediate HCC, and a phase III RCT will compare atezolizumab/bevacizumab against TACE in intermediate-stage disease with a high tumour burden not suitable for transplant [81]. Here, VEGFA is linked to hepatocellular carcinoma.